The research proposed in this application is intended to examine the effects of age on plasticity and repair in the damaged dopamine (DA) system. The primary model to be used in this research is the MPTP-treated mouse. A comparative analysis of the effects of GM1 ganglioside and putative DAergic neurotrophic factors in young mice with and without significant substantia nigra (SN) DA cell loss and in aged mice with significant SN cell loss will be performed. These studies will provide information concerning the ability of trophic factors to stimulate recovery in the DA system under different lesion conditions and to assess the effect of age on the trophic response.
The specific aims of the proposed research are to: 1)compare the effects of GM1 ganglioside, bFGF, IFG-I, BDNF and EGF and the effects of GM1 alone and in combination with the above-mentioned trophic factors in young mice with different degrees of MPTP-induced damage and in aged mice. These studies will assess in vivo regenerative capacity and response of the DA system to trophic influences under the conditions mentioned above; 2) examine possible mechanisms responsible for increases in striatal DA in young MPTP-lesioned mice and in medial forebrain bundle transected rats, and; 3) examine possible mechanisms contributing to age-related decline in GMl effectiveness. Mechanistic issues will be addressed with in vivo studies and more directly by studying GM1 and trophic factor effects on cultured DA neurons exposed to the toxin MPP+. These studies will specifically examine the extent to which GM1-induced recovery in the DA system is due to a biochemical up-regulation of remaining DA neurons and/or a sprouting response. DA turnover, DA uptake, tyrosine hydroxylase (TH) and GAP-43 immunohistochemistry and TH, GAP-43, and tubulin in situ hybridization will be studied in vivo and in vitro. These studies, should provide basic information concerning the effects of GM1 and other trophic agents on the damaged DA system in young and aged animals and provide further insight into basic mechanisms of these responses. This work might have potential clinical significance for the future treatment of degenerative CNS disorders and particularly disorders such as Parkinson's disease which are associated with aging.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG010280-01A1
Application #
3122252
Study Section
Neurology B Subcommittee 2 (NEUB)
Project Start
1992-09-30
Project End
1995-07-31
Budget Start
1992-09-30
Budget End
1993-07-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Allegheny University of Health Sciences
Department
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19129
Schneider, J S (1998) GM1 ganglioside in the treatment of Parkinson's disease. Ann N Y Acad Sci 845:363-73
Rothblat, D S; Schneider, J S (1998) The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons. Brain Res 779:226-30
Schneider, J S; DiStefano, L (1995) Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments. Brain Res 674:260-4
Schneider, J S; Distefano, L (1995) Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion. Neuropharmacology 34:489-93
Schneider, J S; Kean, A; DiStefano, L (1995) GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J Neurosci Res 42:117-23
Stull, N D; Schneider, J S; Iacovitti, L (1994) GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP(+)-induced damage: dependence on initial damage and time of treatment. Brain Res 640:308-15
Schneider, J S; DiStefano, L (1994) Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism. Neurology 44:748-50
Schneider, J S; Smith, M G; DiStefano, L et al. (1994) GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse. Brain Res 636:353-6
Schneider, J S; DiStefano, L (1993) LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment. Neuroreport 5:103-4